A Phase 3 interventional study of Metformin-Sitagliptin-Empaglifozin-Pioglitazone and Standard of care in Newly Diagnosed Type 2 Diabetes, sponsored by Azienda Ospedaliero-Universitaria di Parma. Completed at 1 site in Italy. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Azienda Ospedaliero-Universitaria di Parma · Phase 3, Interventional, and Treatment
Epidemiologic, social and economic burdens of type 2 diabetes mellitus (T2DM) keep rising worldwide. Implementation of T2DM preventive trategies is lagging behind. Metabolic surgery, very low calorie diet can induce T2DM remission, but so far for few patients. The investigators will assess the efficacy to cause T2DM remission (primary end point) and direct costs to the National Health System of a 4-month polychemotherapy (metformin+pioglitazone+sitagliptin+empagliflozin) regimen vs standard care in patients with newly diagnosed T2DM by an open label, pragmatic RCT. Mechanisms of action will be investigated in a sub-cohort by a prolonged OGTT plus dual tracer technique and modeling of beta cell function.
If proved efficacious in this proof-of-concept study and inducer of durable remission in the future, T2DM polychemotherapy will turn out to be a convenient, relatively unexpensive strategy to restrain prevalence of T2DM and its complications and to alleviate its personal, social and economic burden.
Hypothesis: at diagnosis of T2DM, a 4 month course of oral polychemotherapy (POLYCHEM), by engaging multiple glucose lowering mechanisms, results into euglycemia and, after suspension, in T2DM remission in a clinically significant higher number of patients when compared to standard diabetes care (SDC).
Based on the "Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes" published on Diabetes Care 2021;44(10):2438-2444, remission should be defined as a return of HbA1c to \<6.5% (\<48 mmol/mol) that occurs spontaneously or following an intervention and that persists for at least 3 months in the absence of usual glucose-lowering pharmacotherapy.
A POLYCHEM (metformin, pioglitazone, sitagliptin and empagliflozin) will be used to improve:
In many patients POLYCHEM should result in stable euglycemia, with negligible risk of hypoglycemia, and the number of patients in T2DM remission should be much higher than with MET+SU. The underpinning is that euglycemia reverses the detrimental effects of glucose toxicity and glucose regulation can be maintained in the nondiabetic range.
If the invesigators hypothesis is proved, POLYCHEM would be a convenient, simple and relatively unexpensive strategy to induce remission in a great number of patients with newly diagnosed T2DM. Novel, more efficacious goals of therapy could be introduced. Duration of remission is expected to delay the processes which result into the T2DM related risk of tissue damage. At the patient acceptance level, the trade off between the full T2DM burden (diabetes, its care and the risk of its complications) and the risk of T2DM relapse should favor the latter. At the society level, achieving a durable remission in a substantial number of these patients should attenuate, or even annull, the rises in prevalence, burden and tolls of "active" T2DM.
Patients with newly diagnosed (i.e. less than 6 months) T2DM will be recruited in the Diabetes Outpatient Clinics and will provide informed written consent before participation. After a screening visit (V0), patients will be randomized 1:1, with center stratification through web-based data collection (eCRF), to receive POLYCHEM or SDC with standard lifestyle intervention in both.
In both arms, patients will undergo planned visits at week 0 (V1), week 16 (V2), and week 28 (V3), after at least 3 days of drug washout. Patients will perform weekly a 6-point home blood glucose profile. Between week 17 and week 28, if a patient in hyperglycemia remission relapses, V3 will be anticipated (V3B), after which the patient will be treated as in SDC and will be re-evaluated at week 28 .
Visit procedures:
POLYCHEM-ARM: After V1, patients will start POLYCHEM (MET titrated to 1000 mg b.i.d., PIO 15 mg b.i.d., SITA 100 mg q.d., EMPA 10 mg q.d.) for 16 weeks, at the end of which (V2) patients in hyperglycemia remission stop drug therapy, the others are transferred to SDC. Patients with MET intolerance will be treated with PIO+SITA+EMPA only.
SDC-ARM: After V1, patients will continue their SDC for 16 weeks, at the end of which (V2) patients in hyperglycemia remission stop drug therapy, the others continue SDC.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 108 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Azienda Ospedaliero-Universitaria di Parma is the lead sponsor of 43 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
Drug: Metformin-Sitagliptin-Empaglifozin-Pioglitazone
Standard of care according to the local health service.
Drug: Standard of care
1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
Also known as: POLYCHEM
Usual medical care to treat diabetes.
Also known as: SDC
Assess the T2DM remission rate in patients with newly diagnosed T2DM treated with either POLYCHEM or with SDC for 16 weeks.
Remission was defined as HbA1c \<6.5% or 48mmol/mol for at least 12 weeks without pharmacologic or surgical treatment for diabetes.
Time frame: 12 weeks after the end of treatment
Assess the proportion of complete T2DM remission rate in the 2 groups
Normal measures of glucose metabolism (fasting glucose and HbA1c in normal range), for at least 12weeks without pharmacologic or surgical treatment for diabetes.
Time frame: 12 weeks after the end of treatment
Monitor the quality of life EQ-5D-DL
Will be monitored through EQ-5D-DL questionnaires.
Time frame: 0, 16, 28 weeks
Monitor the quality of life ADDQOL
QoL will be monitored through ADDQOL questionnaires.
Time frame: 0, 16, 28 weeks
Monitor the costs of National Health System service utilization
All accesses to the National Healthcare System resources by each patient (visits, treatments, supplies, hospital admissions, etc.) will be retrieved from the Regional Health Registries and recorded. Costs will be assessed from a public purchaser perspective. For this reason all costs will refer to the reimbursement provided to the health facilities by the national health system.
Time frame: 0, 16, 28 weeks
Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation
In all patients C-peptide will be used to compute static surrogate indexes of insulin sensitivity and beta cell function.
Time frame: 0, 16, 28 weeks
Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation
In all patients insulin values will be used to compute static surrogate indexes of insulin sensitivity and beta cell function.
Time frame: 0, 16, 28 weeks
Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation
Glucagon values will provide indexes of alpha cell function and of gut K- and L-cell function. Their role in predicting and/or explaining T2DM remission and/or relapse will be assessed.
Time frame: 0, 16, 28 weeks
Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation
GLP-1 values will provide indexes of alpha cell function and of gut K- and L-cell function. Their role in predicting and/or explaining T2DM remission and/or relapse will be assessed.
Time frame: 0, 16, 28 weeks
Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation
GIP values will provide indexes of alpha cell function and of gut K- and L-cell function. Their role in predicting and/or explaining T2DM remission and/or relapse will be assessed.
Time frame: 0, 16, 28 weeks
Plan to share: No
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria di Parma